| abstract |
The present application provides, among others, antibodies or antigen-binding fragments thereof, to target cell surface GRP78 expressed in tumor cells, tumor endothelial cells, and oncogenic cancer cells. The anti-GRP78 antibody, or antigen-binding fragment thereof, has a high affinity for GRP78 and is less immunogenic in comparison to a given species, e. G., Unmodified parent antibody in humans, and has the ability to inhibit GRP78 . Importantly, this isolated new antibody and its antigen-binding fragments attenuate PI3K signaling in tumor cells and promote apoptosis, while leaving normal cells unaffected. Antibodies and antigen-binding fragments are useful for treating UPR-targeted cancer therapies. |